Long-term cardiovascular outcomes of biodegradable polymer drug eluting stents in patients with diabetes versus non-diabetes mellitus: a meta-analysis
Authors' conclusion
Diabetes mellitus was an independent risk factor associated with long term adverse cardiovascular outcomes following PCI with BP-DES.
Study context
- Population
- Patients undergoing percutaneous coronary intervention (PCI) with biodegradable polymer drug eluting stents (DES) (biodegradable polymer DES (BP-DES)), enrolled 2006–2013; mean follow-up 12 to 120 months
- Participants
- 10,246 patients7 studies
- Comparison
- Diabetes mellitus (DM) vs non-DM patients implanted with BP-DES
- Outcome
- Long-term adverse cardiovascular outcomes
- Follow-up
- ≥ 12 months
Methodological detailsMantel-Haenszel risk ratios
- Mantel-Haenszel risk ratios
Pooled result
As reported in the abstract
Long-term adverse CV outcomes
Each group vs Non-DMEstimate (95% CI)P value
DM
RR, MACE 1.30(1.18–1.43)
P = 0.00001DM
RR, MI 1.48(1.14–1.93)
P = 0.003DM
RR, all-cause mortality 1.70(1.29–2.23)
P = 0.0002DM
RR, cardiac death 1.93(1.28–2.93)
P = 0.002DM
RR, target vessel revascularization 1.35(1.03–1.77)
P = 0.03DM
RR, target lesion revascularization 1.28(1.07–1.54)
P = 0.007DM
RR, target lesion failure 1.79(1.52–2.12)
P = 0.00001DM
RR, definite and probable stent thrombosis 1.80(1.28–2.55)
P = 0.0009Original publication
Long-term cardiovascular outcomes of biodegradable polymer drug eluting stents in patients with diabetes versus non-diabetes mellitus: a meta-analysis. Cardiovasc Diabetol. Published 29 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →